
Vir Biotechnology Announces Positive Chronic Hepatitis Delta Trial Data and Phase 3 Program Launch
Vir Biotechnology, Inc. (NASDAQ:VIR) today revealed positive results from the SOLSTICE Phase 2 clinical trial evaluating its investigational combination of tobevibart and elebsiran for the treatment of chronic hepatitis delta…












